At least nine clinical compounds aim to treat Alzheimer's disease (AD) by targeting the proteolytic processing or production of amyloid precursor protein (APP). At least eight programs are in research/preclinical development. Source: BioCentury Online Intelligence

Company

Product

Description

Status

AC Immune S.A.

ACI-91

Oral small molecule that modulates beta-site APP-cleaving enzyme 1 (BACE1)

Ph II